2027 plan exits to impact ~600K members but recapture expected
Humana's FY2026 Q2 call was characterized by a reaffirmation of its long-term margin targets, a detailed defense of its STARS progress, and a focus on operational efficiency. Management highlighted plans to continue exiting underperforming plans (~600k members) and centralizing operations to drive G&A savings. The market-relevant signals include the divestiture of its Gentiva stake and an expectation of meaningful margin expansion in 2027. FY26 trend guidance of 7-8% is on track; inpatient costs show slight favorability, especially in value-based care settings.
Buzzberg read2027 plan exits to impact ~600K members but recapture expectedHumana's FY2026 Q2 call was characterized by a reaffirmation of its long-term margin targets, a detailed defense of its STARS progress, and a focus on operational efficiency. Management highlighted plans to continue exiting underperforming plans (~600k members) and centralizing operations to drive G&A savings. The market-relevant signals include the divestiture of its Gentiva stake and an expectation of meaningful margin expansion in 2027. FY26 trend guidance of 7-8% is on track; inpatient costs show slight favorability, especially in value-based care settings.Read full analysisCollapse analysis
Humana's FY2026 Q2 call was characterized by a reaffirmation of its long-term margin targets, a detailed defense of its STARS progress, and a focus on operational efficiency. Management highlighted plans to continue exiting underperforming plans (~600k members) and centralizing operations to drive G&A savings. The market-relevant signals include the divestiture of its Gentiva stake and an expectation of meaningful margin expansion in 2027. FY26 trend guidance of 7-8% is on track; inpatient costs show slight favorability, especially in value-based care settings.
Management expects 'meaningful progress' on MA margin expansion in 2027, with the 3% pre-tax margin goal in 2028 unchanged.
Plan exits for 2027 will impact ~600k members (down from 2025's level) as management prioritizes higher return/value-based plans.
STARS performance for BY28 is tracking well, with a new focus on STARS revenue PMPM; the company will enter a blackout period in August.
Revenue$40.867B
+3% QoQ
EPS$7.61
-26% QoQ
Gross margin13.45%
reported
Op margin3.33%
reported
What changed this quarter
01
Margins
2027 plan exits to impact ~600K members but recapture expected
Reported gross margin was 13.45%, reinforcing the quarter's better-than-guided profitability.
02
STARS
STARS improvement shows robust progress on 11 of 12 metrics
FY26 trend guidance of 7-8% is on track; inpatient costs show slight favorability, especially in value-based care settings.
03
Capital Allocation
Gentiva divestiture valued at ~$900M to fund MaxHealth acquisition
Management expects 'meaningful progress' on MA margin expansion in 2027, with the 3% pre-tax margin goal in 2028 unchanged.
04
Efficiency
Operating model changes yielded hundreds of millions in value in 2026
Plan exits for 2027 will impact ~600k members (down from 2025's level) as management prioritizes higher return/value-based plans.
AI, capex & demand read
AI
Platform & monetization
Management highlighted the addition of Paul Smith, Chief Commercial Officer at Anthropic, to the Board of Directors, bringing expertise in leading organizations through major technology transitions. They also mentioned leveraging automation and AI in operations to drive efficiencies and innovation, and referenced the potential for technology benefits over time.
Demand
Bookings & conversion
Management reiterated confidence in achieving its 2028 margin target of at least 3%, with meaningful progress expected in 2027, driven by cost actions and bidding strategy. The tone is cautiously optimistic with a focus on execution.
Tone · Confident
Management expressed confidence in meeting 2028 commitments, highlighted strong operational progress on STARS and cost transformation, and reiterated on-track performance.
Supply-chain alpha
A1
Humana is centralizing 11 markets' utilization management into one team, a step beyond simple vendor consolidation, indicating deep operational restructuring.
Inpatient favorability is concentrated in members engaged with value-based providers, which limits the financial benefit passing through to Humana but validates the VBC model.
Jim RechtinPresident and Chief Executive Officer, Humana
… in 2026. Our member growth is expected to further fuel our ability to unlock the earnings potential of the business. We're making good progress on STARS. We expect to make meaningful progress on MA margin expansion in 27, and we remain on track to hit our investor day commitments in 28. Before I turn it over to Celeste, I would like to highlight our announcement this morning that Paul Smith and Fred Crawford will join Humana's Board of Directors. Paul is the Chief Commercial Officer at Anthropic, where he leads commercial strategy and global go-to-market operations. Paul brings over 30 years of experience leading global organizations through major technology transitions. Fred has deep financial and operational experience, having spent more than 30 years in the insurance and banking industries. Fred was the Chief Financial Officer of three publicly traded insurers and most recently served as the President and Chief Operating Officer at Aflac, until his retirement in 2024. Paul and Fred will complement our board's expertise well, bringing a unique perspective that will be invaluable as we advance along our journey of becoming a consumer healthcare company. With that, I will turn …
Humana is centralizing 11 markets' utilization management into one team, a step beyond simple vendor consolidation, indicating deep operational restructuring. — This is a permanent reduction in medical management scope, which could pressure managed care vendors providing UM services.
Jim RechtinPresident and Chief Executive Officer, Humana
… Our goals have been threefold. First, to be simpler, leaner, and faster, so driving efficiencies while reducing friction for our customers. Second, to lead on innovation, leveraging automation and AI and the best performing vendors. And third, to attract the best talent and ensure effective performance management. Let me provide examples to bring these changes to life. We are centralizing certain operations to simplify process and reduce variability in outcomes. One example is utilization management, where we centralized 11 markets into one team. This is driving G&A savings, but it is also creating more consistent experience for providers and members. We are also expanding outsourcing while improving vendor performance. This year, we increased outsourcing in our finance and HR functions, while we also continued to advance vendor optimization efforts in IT. We are also in the early stages of transforming select other vendor relationships from tactical labor-based engagements into strategic partnerships that can deliver greater business value and capabilities. Finally, we integrated our Care Plus operations. Care Plus is a legacy health plan acquisition that we integrated into our …
Inpatient favorability is concentrated in members engaged with value-based providers, which limits the financial benefit passing through to Humana but validates the VBC model. — While positive for provider partners, Humana's profit growth is constrained by this mix, suggesting a slower margin recovery than headline numbers imply.
… and capital optimization. Starting with 26, based on available information to date, cost trends are in line with our expectations for both new and existing members. As a reminder, we assume 2026 cost trend would be in the high single digit range or seven to 8% inclusive of both medical and pharmacy. There are certain areas where we have seen slight favorability, particularly in the inpatient space. Based on approximately four months of completed claims data, favorability has been more heavily concentrated in members engaged with value-based providers. While the risk-sharing nature of these agreements limit the favorability that flows through to our financials, it is positive for our provider partners and we believe an additional proof point of broader stabilization in the MA trend environment. And as Jim described, our transformation and operating model work is driving the intended results. Our 2Q consolidated operating cost ratio is down 120 basis points year over year. We continue to expect a full year reduction of approximately 150 basis points. Taken together, we are executing and delivering results in line with expectations and remain on track to double our individual MA …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.